Portfolio Design Labs LLC Purchases Shares of 2,417 Novo Nordisk A/S (NYSE:NVO)

Portfolio Design Labs LLC acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the fourth quarter, Holdings Channel reports. The fund acquired 2,417 shares of the company’s stock, valued at approximately $208,000.

Other institutional investors have also made changes to their positions in the company. Natixis Advisors LLC lifted its stake in Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares during the period. Norman Fields Gottscho Capital Management LLC raised its holdings in shares of Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after buying an additional 19,870 shares in the last quarter. Versant Capital Management Inc bought a new position in shares of Novo Nordisk A/S during the 4th quarter worth approximately $86,000. Talbot Financial LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at $4,066,000. Finally, Clear Creek Financial Management LLC bought a new stake in Novo Nordisk A/S in the fourth quarter valued at $450,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $81.78 on Thursday. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.75 and a debt-to-equity ratio of 0.62. The firm’s 50 day moving average is $90.45 and its 200-day moving average is $110.60. The firm has a market capitalization of $366.99 billion, a price-to-earnings ratio of 24.86, a PEG ratio of 0.96 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Sell-side analysts forecast that Novo Nordisk A/S will post 3.86 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a $0.7874 dividend. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 21.88%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on NVO shares. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Wednesday. They issued an “equal weight” rating for the company. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.